| Schedule of Segment Reporting Financial Information |
The following table presents selected financial information with respect to the Company’s single operating segment for the three and nine months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Royalty revenue |
|
$ |
14,359 |
|
|
$ |
18,314 |
|
|
$ |
50,133 |
|
|
$ |
50,199 |
|
Total revenue |
|
|
14,359 |
|
|
|
18,314 |
|
|
|
50,133 |
|
|
|
50,199 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
RSV |
|
|
5,893 |
|
|
|
15,412 |
|
|
|
15,746 |
|
|
|
51,620 |
|
Total virology |
|
|
5,893 |
|
|
|
15,412 |
|
|
|
15,746 |
|
|
|
51,620 |
|
KIT |
|
|
4,232 |
|
|
|
4,057 |
|
|
|
12,803 |
|
|
|
11,902 |
|
STAT6 |
|
|
7,083 |
|
|
|
4,678 |
|
|
|
20,578 |
|
|
|
10,670 |
|
MRGPRX2 |
|
|
3,368 |
|
|
|
2,292 |
|
|
|
8,237 |
|
|
|
6,840 |
|
Total immunology |
|
|
14,683 |
|
|
|
11,027 |
|
|
|
41,618 |
|
|
|
29,412 |
|
Early discovery |
|
|
1,421 |
|
|
|
603 |
|
|
|
4,572 |
|
|
|
1,115 |
|
Other pipeline programs |
|
|
129 |
|
|
|
168 |
|
|
|
492 |
|
|
|
784 |
|
Total other programs |
|
|
1,550 |
|
|
|
771 |
|
|
|
5,064 |
|
|
|
1,899 |
|
General and administrative |
|
|
9,469 |
|
|
|
9,997 |
|
|
|
28,046 |
|
|
|
34,231 |
|
Total operating expenses |
|
|
31,595 |
|
|
|
37,207 |
|
|
|
90,474 |
|
|
|
117,162 |
|
Loss from operations |
|
|
(17,236 |
) |
|
|
(18,893 |
) |
|
|
(40,341 |
) |
|
|
(66,963 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(4,130 |
) |
|
|
(1,618 |
) |
|
|
(10,529 |
) |
|
|
(5,294 |
) |
Interest and investment income, net |
|
|
1,901 |
|
|
|
2,285 |
|
|
|
6,407 |
|
|
|
7,376 |
|
Total other (expense) income, net |
|
|
(2,229 |
) |
|
|
667 |
|
|
|
(4,122 |
) |
|
|
2,082 |
|
Loss before income taxes |
|
|
(19,465 |
) |
|
|
(18,226 |
) |
|
|
(44,463 |
) |
|
|
(64,881 |
) |
Income tax (expense) benefit |
|
|
(36 |
) |
|
|
(29 |
) |
|
|
(67 |
) |
|
|
1,692 |
|
Net loss |
|
$ |
(19,501 |
) |
|
$ |
(18,255 |
) |
|
$ |
(44,530 |
) |
|
$ |
(63,189 |
) |
|